n/a
n/a
The present invention relates to a method and system for high-voltage radiofrequency ablation using combined heat and electroporation to produce a deeper lesion while avoiding the production of excess heat at the tissue surface.
The use of an electric field is relatively new medical treatment for such purposes as the enhancement of chemotherapy (electrochemotherapy), cellular ablation, and intracellular electromanipulation. All three treatments involve pulses of energy, although using different frequencies and pulse durations. Ablation, such as of tumor or liver cells, occurs when cells are exposed to high-voltage electrical field pulses. In the presence of these pulses, the electrochemical potential across the cell membrane is altered and instabilities in the polarized lipid bilayer are induced, which may lead to the development of irreversible pores (or enlargement of existing pores) in the cell membrane. The phenomenon may cause cell death through the loss of cellular contents or entry of surrounding contaminants.
This increase in cell membrane permeability when exposed to an electric field is generally referred to as electroporation, and may be brought about by the application of pulses of direct current (DC) electrical energy applied internally (via, for example, a catheter) or externally. However, the repetition frequency of electric pulses is considered to effect muscle contractions, which can produce a burning sensation or intense pain in patients.
Further, deep lesions are sometimes required to effectively treat some cardiac conditions. For example, atrial fibrillation may be caused by aberrant electrical conductivity pathways through and around scarred myocardial tissue, which cause an electrical “feedback loop” and irregular heartbeat. To destroy these aberrant pathways, the myocardial tissue must be ablated deeply enough to stop the problematic electrical signals from continuing. The creation of deep lesions requires prolonged application of energy and/or high temperatures. However, the surface of the tissue must be maintained at cool enough temperatures to avoid charring or micro embolus formation, which can lead to unintended tissue death or stroke.
Therefore, a system and method are desired that is capable of producing deep lesions without the production of high heat and without causing patient discomfort. The system and method of the present invention involve the application of higher voltage radiofrequency energy to use both heat and electroporation to perform ablation while avoiding undesired tissue damage due to excess heat at the tissue surface.
The present invention advantageously provides a method and system for producing deep lesions without the production of high heat. The method generally includes treating target tissue cells using a medical device that is configured to selectively deliver energy at a voltage at which tissue electroporation occurs, energy at a voltage at which heat ablation occurs, or any voltage therebetween. The medical device may also be configured to reduce the temperature of the tissue cells to a temperature at which cryoablation occurs. The applied energy may be radiofrequency (RF) energy, and the RF energy may be an alternating current energy having a frequency of between approximately 20 kHz and approximately 1 MHz. Electroporation energy may be delivered between approximately 500 volts RMS and approximately 3000 volts RMS. Further, a voltage at which heat ablation occurs is applied to target tissue cells before applying a voltage at which electroporation occurs. Still further, the medical device may include a plurality of electrodes and radiofrequency energy is delivered to each of the plurality of electrodes, the energy delivered to each of the plurality of electrodes being either at in-phase angle or out-of-phase angle relative to the energy delivered to adjacent electrodes.
In an another embodiment, the method may include positioning a medical device in contact with an area of target tissue, the medical device including a plurality of electrodes in communication with a radiofrequency generator, the generator programmable to deliver energy in at least one of bipolar mode and combination of unipolar mode and bipolar mode, delivering to the target tissue both radiofrequency energy from the medical device at between approximately 500 volts RMS to approximately 3000 volts RMS, and delivering alternating current radiofrequency energy from the medical device at between approximately 100 volts RMS to approximately 150 volts RMS to an area of target tissue. The method may further include delivering alternating current radiofrequency energy at a voltage between approximately 150 volts RMS and approximately 500 volts RMS. The energy delivered to each of the plurality of electrodes may be delivered at either an in-phase angle or out-of-phase angle relative to the energy delivered to adjacent electrodes.
The system may generally includes a medical device having a plurality of electrodes at a distal end of the device, and energy generator in communication with the plurality of electrodes, the generator programmable to deliver between approximately 100 volts RMS and approximately 3000 volts RMS. The device may further include one or more sensors at the distal end. The energy generator may be programmable to deliver between approximately 100 volts RMS and approximately 150 volts RMS during a first treatment cycle and between approximately 500 volts RMS and approximately 3000 volts RMS during a second treatment cycle. Further, the energy generator may be programmable to deliver energy to the plurality of electrodes in at least one of unipolar mode, bipolar mode, and combination thereof.
A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
The present invention provides systems and methods of use thereof for producing deep lesions without the production of high heat and without causing patient discomfort. High-frequency alternating current (AC) radiofrequency (RF) energy may is used (for example, between approximately 20 kHz and approximately 1 MHz, as this range does not stimulate the heart but still provides an electrophoretic effect) is used to ablate tissue through either cellular electroporation or heat or a combination thereof, while maintaining tissue surface temperatures below a threshold temperature that causes unintentional charring or the formation of micro emboli. Further, this application of AC RF energy does not cause patient discomfort or pain as does the application of DC energy. Still further, the AC RF energy may be applied at a voltage capable of ablating tissue due to heat energy, a voltage capable of ablating tissue due to electroporation effects, or a voltage at any point along a continuum between heat energy and electroporation energy. Referring now to the drawing figures in which like reference designations refer to like elements,
Referring to
The catheter 14 may define one or more lumens 28 for providing mechanical, electrical, and/or fluid communication between the proximal portion 22 and the distal portion 24 of the elongate body 20. The one or more lumens 28 may be thermally insulated to substantially prevent heat exchange between, for example, a lumen 28 (and any devices or components therein) and the plurality of electrodes 26. The distal portion 24 of the elongate body 20 may further include one or more sensors 29 for detecting pressure, temperature, electrical impedance, or other system and/or environmental parameters (for example, the surface temperature of the target tissue 12). The one or more sensors 29 may be of any configuration (for example, ring sensors as shown in
The proximal portion 22 of the elongate body 20 may be coupled to a handle 30, which may include various ports for electrical and fluid connectors, leads, junctions, or tubes, and may also include various control assemblies, such as switches or valves, as well as safety detection or shutdown components. For example, the handle 30 may include connectors that are matable directly or indirectly by way of one or more umbilicals to the console 18. Further, the handle 30 may also include an element such as a lever or knob for manipulating or deflecting at least a portion of the elongate body 20.
Continuing to refer to
The generator 16 may also be capable of operating at a lower voltage (for example, approximately 100 to approximately 150 volts RMS) for ablating tissue using primarily heat energy. To generate heat energy, the RF energy may be delivered in multiple ON/OFF cycles in which the ON cycle is greater than, for example, 2% of the total cycle. Tissue may be irreversibly damaged at temperatures above 45° C.; however, sub-lethal heat energy may be applied to temporarily “stun” (rather than irreversibly damage) an area of target tissue to help determine whether the area of stunned tissue is perpetuating an aberrant electrical signal involved in an arrhythmia, and therefore whether subsequent electroporation of the stunned area of tissue will block the aberrant electrical signal. Because electroporation may not result in immediate ablation of the treated tissue (that is, the treated cells may continue to function somewhat normally for a time after electroporation) and thus immediate current blockage, it may be difficult to determine whether the correct area of tissue was electroporated. Therefore, the combination of heat energy and electroporation may result in more effective and efficient ablation.
The generator 16 may allow for the selection of simultaneous or selective energy delivery across electrode pairs, and may further include a user interface 32 for monitoring ablation time, electrode temperature, time at temperature, and the like. The energy output scheme of the generator 16 may be programmable independently of the console 18 via the user interface 32. Further, the generator 16 may be capable of delivering an adjustable voltage so ablation may be caused using primarily heat (for example, between approximately 100 V to approximately 150 V), primarily electroporation (for example, between approximately 500V and approximately 2000 V or more), or any combination thereof (a voltage anywhere along the continuum between heat voltage and electroporation voltage). Additionally, the generator 16 may be programmable to manipulate characteristics of the energy output, such as the ON cycle percentage of the total duty cycle, the voltage, and the number of ON/OFF sequences. In a non-limiting example, the voltage could be adjusted to alternately ablate tissue 12 using primarily heat, primarily electroporation, or combination thereof. In an additional non-limiting example, cryoablation may be used in addition to electroporation (as shown in
Continuing to referring to
Referring now to
All four electrodes may be activated to apply energy at 1000 V RMS in bipolar mode (as shown in
Referring now to
In Step 2 of
In Step 5 of
After completion of Steps 1-6, the target tissue 12 is ablated. In Step 7 of
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings without departing from the scope and spirit of the invention, which is limited only by the following claims.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4813934 | Engelson et al. | Mar 1989 | A |
| 4846174 | Willard et al. | Jul 1989 | A |
| 4968300 | Moutafis et al. | Nov 1990 | A |
| 5281213 | Milder et al. | Jan 1994 | A |
| 5397308 | Ellis et al. | Mar 1995 | A |
| 5398683 | Edwards et al. | Mar 1995 | A |
| 5423755 | Kesten et al. | Jun 1995 | A |
| 5447497 | Sogard et al. | Sep 1995 | A |
| 5472441 | Edwards et al. | Dec 1995 | A |
| 5487385 | Avitall | Jan 1996 | A |
| 5575766 | Swartz et al. | Nov 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5617854 | Munsif | Apr 1997 | A |
| 5673695 | McGee et al. | Oct 1997 | A |
| 5725523 | Mueller | Mar 1998 | A |
| 5772681 | Leoni | Jun 1998 | A |
| 5776129 | Mersch | Jul 1998 | A |
| 5868735 | Lafontaine | Feb 1999 | A |
| 5910154 | Tsugita et al. | Jun 1999 | A |
| 5928193 | Campbell | Jul 1999 | A |
| 5938660 | Swartz et al. | Aug 1999 | A |
| 5964778 | Fugoso et al. | Oct 1999 | A |
| 5971979 | Joye et al. | Oct 1999 | A |
| 5980486 | Enger | Nov 1999 | A |
| 6012457 | Lesh | Jan 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6036697 | DiCaprio | Mar 2000 | A |
| 6088614 | Swanson | Jul 2000 | A |
| 6129724 | Fleischman et al. | Oct 2000 | A |
| 6161543 | Cox et al. | Dec 2000 | A |
| 6164283 | Lesh | Dec 2000 | A |
| 6179810 | Wantink et al. | Jan 2001 | B1 |
| 6179827 | Davis et al. | Jan 2001 | B1 |
| 6214002 | Fleischman et al. | Apr 2001 | B1 |
| 6233491 | Kordis et al. | May 2001 | B1 |
| 6237604 | Burnside et al. | May 2001 | B1 |
| 6241754 | Swanson et al. | Jun 2001 | B1 |
| 6245064 | Lesh et al. | Jun 2001 | B1 |
| 6254599 | Lesh et al. | Jul 2001 | B1 |
| 6283959 | Lalonde et al. | Sep 2001 | B1 |
| 6290696 | Lafontaine | Sep 2001 | B1 |
| 6305378 | Lesh | Oct 2001 | B1 |
| 6312407 | Zadno-Azizi et al. | Nov 2001 | B1 |
| 6325797 | Stewart et al. | Dec 2001 | B1 |
| 6355029 | Joye et al. | Mar 2002 | B1 |
| 6387092 | Burnside et al. | May 2002 | B1 |
| 6416511 | Lesh et al. | Jul 2002 | B1 |
| 6428536 | Panescu et al. | Aug 2002 | B2 |
| 6432102 | Joye et al. | Aug 2002 | B2 |
| 6471694 | Kudaravalli et al. | Oct 2002 | B1 |
| 6502576 | Lesh | Jan 2003 | B1 |
| 6514245 | Williams et al. | Feb 2003 | B1 |
| 6514249 | Maguire et al. | Feb 2003 | B1 |
| 6517514 | Campbell | Feb 2003 | B1 |
| 6517533 | Swaminathan | Feb 2003 | B1 |
| 6572612 | Stewart et al. | Jun 2003 | B2 |
| 6575966 | Lane et al. | Jun 2003 | B2 |
| 6578579 | Burnside et al. | Jun 2003 | B2 |
| 6585733 | Wellman | Jul 2003 | B2 |
| 6595988 | Wittenberger et al. | Jul 2003 | B2 |
| 6602276 | Dobak, III et al. | Aug 2003 | B2 |
| 6626861 | Hart et al. | Sep 2003 | B1 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6641511 | Patel et al. | Nov 2003 | B2 |
| 6645234 | Evans et al. | Nov 2003 | B2 |
| 6648878 | Lafontaine | Nov 2003 | B2 |
| 6648879 | Holland et al. | Nov 2003 | B2 |
| 6648883 | Francischelli et al. | Nov 2003 | B2 |
| 6652515 | Maguire et al. | Nov 2003 | B1 |
| 6659981 | Stewart et al. | Dec 2003 | B2 |
| 6666858 | Lafontaine | Dec 2003 | B2 |
| 6685732 | Kramer | Feb 2004 | B2 |
| 6689128 | Sliwa, Jr. et al. | Feb 2004 | B2 |
| 6702811 | Stewart et al. | Mar 2004 | B2 |
| 6738673 | Desai | May 2004 | B2 |
| 6740104 | Solar et al. | May 2004 | B1 |
| 6755822 | Reu et al. | Jun 2004 | B2 |
| 6758847 | Maguire | Jul 2004 | B2 |
| 6780183 | Jimenez, Jr. et al. | Aug 2004 | B2 |
| 6811550 | Holland et al. | Nov 2004 | B2 |
| 6837886 | Collins et al. | Jan 2005 | B2 |
| 6875209 | Zvuloni et al. | Apr 2005 | B2 |
| 6893433 | Lentz | May 2005 | B2 |
| 6929639 | Lafontaine | Aug 2005 | B2 |
| 6952615 | Satake | Oct 2005 | B2 |
| 6989009 | Lafontaine | Jan 2006 | B2 |
| 7029470 | Francischelli et al. | Apr 2006 | B2 |
| 7097641 | Arless et al. | Aug 2006 | B1 |
| 7097643 | Cornelius et al. | Aug 2006 | B2 |
| 7137395 | Fried et al. | Nov 2006 | B2 |
| 7189227 | Lafontaine | Mar 2007 | B2 |
| 7195625 | Lentz | Mar 2007 | B2 |
| 7226446 | Mody et al. | Jun 2007 | B1 |
| 7465300 | Arless et al. | Dec 2008 | B2 |
| 7479141 | Kleen et al. | Jan 2009 | B2 |
| 7519410 | Taimisto et al. | Apr 2009 | B2 |
| 7540853 | Hayzelden | Jun 2009 | B2 |
| 7655005 | Bhola | Feb 2010 | B2 |
| 7674256 | Marrouche et al. | Mar 2010 | B2 |
| 7706894 | Stewart et al. | Apr 2010 | B2 |
| 7740627 | Gammie et al. | Jun 2010 | B2 |
| 20020032406 | Kusleika | Mar 2002 | A1 |
| 20020035361 | Houser et al. | Mar 2002 | A1 |
| 20020045894 | Joye et al. | Apr 2002 | A1 |
| 20020087151 | Mody et al. | Jul 2002 | A1 |
| 20020128636 | Chin et al. | Sep 2002 | A1 |
| 20020183691 | Callister | Dec 2002 | A1 |
| 20020188325 | Hill et al. | Dec 2002 | A1 |
| 20030009160 | Carroll et al. | Jan 2003 | A1 |
| 20030125721 | Yon et al. | Jul 2003 | A1 |
| 20030153905 | Edwards et al. | Aug 2003 | A1 |
| 20030158516 | Wholey et al. | Aug 2003 | A1 |
| 20030199861 | Lafontaine | Oct 2003 | A1 |
| 20040034344 | Ryba | Feb 2004 | A1 |
| 20040073203 | Yu et al. | Apr 2004 | A1 |
| 20040073301 | Donlon et al. | Apr 2004 | A1 |
| 20040082947 | Oral et al. | Apr 2004 | A1 |
| 20040158237 | Abboud et al. | Aug 2004 | A1 |
| 20040225342 | Callister | Nov 2004 | A1 |
| 20050020901 | Belson et al. | Jan 2005 | A1 |
| 20050070887 | Taimisto et al. | Mar 2005 | A1 |
| 20050182393 | Abboud et al. | Aug 2005 | A1 |
| 20050182395 | Lafontaine | Aug 2005 | A1 |
| 20050256521 | Kozel | Nov 2005 | A1 |
| 20050261672 | Deem et al. | Nov 2005 | A1 |
| 20060247611 | Abboud et al. | Nov 2006 | A1 |
| 20060271032 | Chin et al. | Nov 2006 | A1 |
| 20060271093 | Holman et al. | Nov 2006 | A1 |
| 20070078453 | Johnson et al. | Apr 2007 | A1 |
| 20070093710 | Maschke | Apr 2007 | A1 |
| 20070203549 | Demarais et al. | Aug 2007 | A1 |
| 20070233222 | Roeder et al. | Oct 2007 | A1 |
| 20080091180 | Abboud et al. | Apr 2008 | A1 |
| 20080103493 | Abboud et al. | May 2008 | A1 |
| 20080132885 | Rubinsky et al. | Jun 2008 | A1 |
| 20080200912 | Long | Aug 2008 | A1 |
| 20080281391 | MacAdam et al. | Nov 2008 | A1 |
| 20090228003 | Sinelnikov | Sep 2009 | A1 |
| 20090248012 | Maor et al. | Oct 2009 | A1 |
| 20090248014 | Shachar et al. | Oct 2009 | A1 |
| 20090281477 | Mikus et al. | Nov 2009 | A1 |
| 20090299355 | Bencini et al. | Dec 2009 | A1 |
| 20090306641 | Govari et al. | Dec 2009 | A1 |
| 20100023004 | Francischelli et al. | Jan 2010 | A1 |
| 20100114287 | Privitera et al. | May 2010 | A1 |
| 20100137704 | Vij et al. | Jun 2010 | A1 |
| 20100168557 | Deno et al. | Jul 2010 | A1 |
| 20100249771 | Pearson et al. | Sep 2010 | A1 |
| 20100250209 | Pearson et al. | Sep 2010 | A1 |
| 20100261994 | Davalos et al. | Oct 2010 | A1 |
| 20120035601 | Wittenberger | Feb 2012 | A1 |
| 20120071874 | Davalos et al. | Mar 2012 | A1 |
| 20120109118 | Lalonde et al. | May 2012 | A1 |
| 20120123411 | Ibrahim et al. | May 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 0896211 | Feb 1999 | EP |
| 0957758 | Nov 1999 | EP |
| 1383426 | Jan 2004 | EP |
| 9406349 | Mar 1994 | WO |
| 9634571 | Nov 1996 | WO |
| 9902096 | Jan 1999 | WO |
| 0007657 | Feb 2000 | WO |
| 0042932 | Jul 2000 | WO |
| 0122897 | Apr 2001 | WO |
| 0160441 | Aug 2001 | WO |
| 0207628 | Jan 2002 | WO |
| 02083196 | Oct 2002 | WO |
| 03020334 | Mar 2003 | WO |
| 03026719 | Apr 2003 | WO |
| 03039338 | May 2003 | WO |
| 2005067668 | Jul 2005 | WO |
| 2005089853 | Sep 2005 | WO |
| 2006058251 | Jun 2006 | WO |
| 2006118725 | Nov 2006 | WO |
| 2007079438 | Jul 2007 | WO |
| 2008000065 | Jan 2008 | WO |
| 2008142686 | Nov 2008 | WO |
| 2009065042 | May 2009 | WO |
| 2009140067 | Nov 2009 | WO |
| 2010002888 | Jan 2010 | WO |
| 2010006229 | Jan 2010 | WO |
| 2010067360 | Jun 2010 | WO |
| Entry |
|---|
| R. V. Davalos, et al., Tissue Ablation with Irreversible Electroporation, Annals of Biomedical Engineering, vol. 33, No. 2, Feb. 2005 (© 2005) pp. 223-231. |
| International Search Report and Written Opinion dated Dec. 13, 2013 for International Application Serial No. PCT/US2013/056756, International Filing Date: Aug. 27, 2013 consisting of 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20140066913 A1 | Mar 2014 | US |